SLC5A2 and hydrops fetalis: These benefits are supported by more recent suggestions of how to sequence the initiation of HF medications in patients, with one current proposal focusing on getting four drugs “on board” within four weeks and starting both an SGLT2 inhibitor and a beta-blocker in the first instance, as seen in comparison to the ESC Guidelines sequencing approach in Figure 2 [19].